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Abstract
Cancer is a disease characterized by its high morbidity and mortality, mainly due to its
metastatic ability. Metastasis is a multi-step process beginning with detachment of tumor cells
from the primary tumor and leading ultimately to the establishment of a new tumoral site. This
cascade includes intravascular migration of tumor cells either individually or collectively and
the expansion of cancer cells at metastatic sites that is dependent on certain conditions such as
an immunosuppressive environment. In this paper, blockers of tumor cell migration and
suppressors of immunotolerance at metastatic sites are reviewed as an illustration of early and
later phases intervention, respectively. A combination of these two therapeutics will be
advocated based on the proposition of correlation between the pattern of tumor cell migration
and the mechanism of immunotolerance induction. By extension, the ''delayed
complementarity'' will be introduced as an approach to formulate new anticancer
drug combinations.
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Introduction And Background
Metastasis is the ensemble of steps that some tumor cells follow to migrate from a tumor site to
another distant one [1]. First, these cells have to invade through the extracellular matrix (ECM)
to reach a vascular vessel. After they penetrate the vessel wall, they migrate through the
circulatory system either individually as circulating tumor cells (CTC) or collectively as
circulating tumor microemboli (CTM) [2]. Once they have reached the target site, they exit the
vascular system by extravasation, cut across the ECM to reach their new "home". The
development of the metastatic site reflects the survival and proliferation of tumor cells in
the hostile new environment that is facilitated by establishing some favorable conditions such
as immunotolerance towards these cells and a vasculature system for blood supply. Each step of
the cascade is a potential therapeutic target to block the metastatic process. As an illustration,
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Inhibition of tumor cell migration
Collective and individual tumor cell migration inhibitors share a common target which
is cell motility, but they have other specific ones such as intercellular adhesion for collective
migration blockers. Of note, collective migration inhibitors act from the initial step of invasion
at the primary site, given that most probably the cells are clustering at this point [2]. At a
molecular level, the principal actors targeted are Rho GTPases, N-cadherin, and integrins. Rho
GTPases are members of Rho family proteins that act as intracellular transducers mediating the
organization of various types of actin filaments, thus playing an important role in cells
migration. Rho GTPases include many molecules such as RhoA, Rac1, and Cdc42 and have
multiple effectors mainly the Rho-associated coiled coil-containing protein kinases (ROCKs) [3].
In addition to their permissive role in tumor cell migration, Rho GTPases have specific effects
on collective migration by maintaining the front-rear polarity of cell clusters and the stability
of cell-cell junction [4]. Rho GTPases pathway blockers target either Rho GTPases or their
downstream effectors. GGTI-2418 is an inhibitor targeting a post-translational modification
required for the function of Rho proteins. It has progressed to clinical phase I, but the study was
terminated prematurely based on sponsor decision [5]. As for ROCK inhibitors, a drug labeled
AT13148 has completed the phase I, but the results have not been reported yet. Another
approach for targeting this pathway is through nonspecific commonly used drugs that have
shown an inhibitory effect on the Rho GTPases pathway, such as statins and the phytochemical
agent known as rocaglamide [3,6].
Integrins are transmembrane heterodimers formed by α and β subunits that intervene in
collective cell migration by maintaining cells cluster’s cohesion via homophilic integrin-
integrin cell adhesion, and the leader-rear polarity through cytoskeletal coordination [7]. The
α5β1 inhibitor volociximab has progressed to the phase II trial and had demonstrated an
acceptable safety profile. Despite the encouraging preclinical outcomes of β1 integrins
blockade, the clinical benefice was still insufficient [8]. Some possible explanations of the
limited outcomes have been discussed in detail by Alday-Parejo and colleagues, such as the
subtypes of integrins that have been targeted, the methods of blockade used, in addition to
some concerns about preclinical models selected and the designs of clinical trials [9]. 
Another molecule implicated in collective migration is N-cadherin. This transmembrane
protein mediating cell-cell adhesion is expressed by different cells such as endothelial and
neural ones, but also some tumor cells [10]. It is upregulated at the invasive front via the
process of epithelial to mesenchymal transition that precedes tumor cell detachment and
invasion, providing an adherence between the migrating cells. ADH-1, a cyclic pentapeptide, is
the first N-cadherin inhibitor to be tested in the clinical setting. In phase I, it had shown an
acceptable safety profile with some clinical efficacity [11]. More data would be obtained from
recently completed phase II studies. Another class of N-cadherin inhibitors is monoclonal
antibodies that have demonstrated suppressive effects on proliferation, invasion, and
metastasis in vitro and in vivo [12]. Given that N-cadherin is cleaved by proteases such as the
disintegrin and metalloprotease 10 (ADAM10), targeting N-cadherin through ADAM10 agonists
would be rational [13]. Unfortunately, ADAM 10 has nonspecific cleavage activity that may
induce activation of some protumorigenic molecules [14]. This could be the reason for not
including ADAM10 agonists in cancer clinical trials, although its use in other conditions such as
Alzheimer's disease [14]. However, some commonly used anticancer drugs had proven to have
ADAM10 agonist effects such as the synthetic retinoid Am80 (tamibarotene) and the natural
phenol, resveratrol. This incites for an extensive evaluation of ADAM10 agonist effects on
cancer. 
Inhibition of immunomodulation
Immunotolerance provides a favorable environment for migratory tumor cells to develop at
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metastatic sites. It may be achieved by myeloid-derived suppressor cells (MDSCs), even before
the arrival of metastatic cells. MDSCs are a heterogeneous population of immature myeloid
cells that suppress innate and adaptive immunity [15]. This effect is accomplished through
different mechanisms such as the production of reactive nitrogen and oxygen species,
depletion of key nutrients factors for T cells such as L-arginine and L-tryptophan, limiting
immunocompetent cells homing, induction of regulatory T cells, and production of
immunosuppressive cytokines [16]. Tumor cells could also induce immunomodulation as they
arrive at the metastatic site via immunosuppressive checkpoints molecules expressed on their
surface, such as PDL1, TIM-3, B7-H3, B7-H1, CD47, and immunomodulatory secreted factors
such as IL-8, IL-6, and TGFB [15]. The focus in this paper will be on inhibitors of MDSC-induced
immunotolerance.
Broadly, MDSC may be neutralized by at least three different approaches [17]. We can either
block their immunosuppressive effect, limit their homing to metastatic sites, or reduce their
numbers. Suppression of the immunomodulatory effect may be achieved by different drugs.
Some of them are commonly used such as tadalafil, and others are under experimentation such
as STAT3 inhibitors. Tadalafil is a phosphodiesterase type 5 (5PDE) inhibitor that had shown
amelioration of clinical outcomes in patients with head and neck squamous cell carcinoma,
and melanoma [18-19]. These results are due in part to inhibition of MDSC activity through
suppression of NO arg-1 pathways [18]. By the same mechanism, the class I histone deacetylase
inhibitor entinostat had shown an inhibitory effect on MDSC function in preclinical models and
has progressed to phase II trials as a monotherapy and in combination [20]. One of these trials
had already published the results, showing a 24% rate of disease control with entinostat [21].
STAT3 had shown an important role in MDSC immunomodulation, making it a therapeutic
target [22]. There are at least six major classes of STAT3 inhibitors [23]. Napabucasin, an
inhibitor of transcription of STAT3 downstream genes, is actually the only one that had
progressed to phase III clinical trials. It had shown prolongation of overall survival in patients
with positive pSTAT3 advanced colorectal cancer [24]. Antagonism of leukocyte
immunoglobulin-like receptor B, a myeloid receptor intervening in MDSC differentiation and
tumor immune tolerance, seems also a promising approach as it has shown a reprogramming
effect on MDSC toward an antitumoral phenotype [25-26].
Limiting MDSC recruitment to pre-metastatic niches could be achieved by targeting
chemokine/chemokine receptors involved, such as CCL2/CXCR2 or CCR5. CCR5 inhibitors had
shown antitumoral effects on preclinical models and one of them, maraviroc, had been already
approved for clinical use in HIV, facilitating thus the realization of a pilot clinical trial in
patients with advanced metastatic colorectal carcinoma [27]. The drug was well-tolerated, with
evident antitumoral activity at histologic level, and some partial clinical response. As for
CCL2/CXCR2 axis blockade, AZD5069 and SX-682 are two molecules that are currently tested in
phase I and II clinical trials [28]. Lastly, some chemotherapeutic drugs have shown an MDSC
reduction effect such as the anti-CD38 antibody daratumumab that has been approved by the
FDA for multiple myeloma. Studies have shown a depleting effect of daratumumab on MDSC,
given their expression of CD38. The list also includes all-trans retinoic acid (ATRA),
gemcitabine, and 5-fluorouracil. Their effects are exercised through different mechanisms such
as apoptosis and induction of differentiation of MDSC into mature myeloid cells like DC or
macrophages [17].
A general remark about tumor cell migration blockers and tumor immunotolerance inhibitors
is that they both have at best partial response as monotherapy. So, using these inhibitors in
combination with other molecules seems to be a must. The combination is classically
achieved by addition of commonly used chemotherapeutic drugs. In a model of rat sarcoma,
Ten Hagen et al. had shown a synergism between αVβ3/αVβ5 integrin inhibitor cilengitide and
the alkylating agent melphalan [29]. However, the association between cilengitide and
temozolomide chemoradiotherapy did not ameliorate the outcome in a multicenter phase 3
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trial [30]. The selection of drugs may be also based on physiopathological approach. Given that
each metastatic step may be accomplished by different mechanisms that may not all be
suppressed by one inhibitor, combining two inhibitors of the same metastatic step but acting
on different mechanisms is rational. An example extensively tested in experimental models is
the association between MDSC-targeting drugs and immune checkpoint inhibitors. This combo
had shown encouraging outcomes and is adopted by many ongoing clinical trials [31]. In this
paper, an additional physiopathological approach is proposed based on ''delayed
complementarity''. It consists of suppressing metastatic cells that escape a given inhibitor by a
second one acting at a later phase of metastasis. To be applicable, this approach needs a certain
degree of predictability between the two phases that are targeted. That means that tumor cells
following a pathway that is not blocked by the first inhibitor are expected to depend at the later
phase on a mechanism repressible by the second agent. So, can this approach be used to realize
a combination between tumor cells migration inhibitors and immunotolerance suppressors? To
have an answer, we should first find out if there is a correlation between the type of migration
and the modality of immunotolerance induction at the metastatic sites. Theoretically, if the
definitions and characteristics are taken into account, there would be a link. In individual cell
migration, the preponderant mechanism to induce immunotolerance would be via MDSC, as it
would be less probable for single tumor cells to induce important changes in the immune
microenvironment as they arrive. As for collective migrating tumor cells, tumor-induced
immunotolerance would also take part in the process, given the number of tumor cells
migrating simultaneously, and eventually, the presence of cells with an immunosuppressive
ability such as tumor-associated fibroblast,s within the microemboli [32-33]. This implies that
the association between tumor cell migration inhibitors and immune tolerance suppressors
would be possible. An efficient combination of these therapeutics would be achieved by
targeting the collective tumor cell migration and MDSC, given that individual migratory cells
that may escape the collective migration inhibitor would rely later on MDSC for
immunotolerance induction (Figure 1).
FIGURE 1: Schematic illustration of delayed complementarity
between collective tumor cell migration inhibitors and MDSC
suppressors
MDSC, myeloid-derived suppressor cells
Finally, some limitations of the delayed complementarity approach should be taken into
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consideration. It is expected that the success of such a combination would depend heavily on
the suppressive ability of each drug, and so developing therapeutics with greater efficacity is
the challenge to optimize the results. Also, the association of tumor cell migration inhibitors
and immunotolerance blockers is targeting mainly the metastatic process. If
it demonstrates satisfactory results, therapeutic interventions targeting the primary tumoral
site should be considered. Of note, this illustrated combination should be introduced at an
earlier phase of cancer progression, as it is acting on the prevention of metastatic
site formation. 
Conclusions
In the absence of radical treatment for cancer disease, association of available drugs is a
valuable method to ameliorate the clinical outcomes. The combination of therapeutics
targeting different phases of cancer progression that have some predictable connections
between them is the basis of delayed complementarity approach. If validated, this would be an
additional option to formulate more effective anticancer drug combinations. 
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